Clicky

Navamedic ASA(NAVA)

Description: Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.


Keywords: Medicine Pharmaceutical Pharmaceutical Products Pain Pharmacy Antibiotics Rare Diseases Cough Health Care Products Obesity Prescription Drugs Food Supplements Consumer Health Products Phenylketonuria Cardiology Products Urea Cycle Disorders Renal Diseases Homocystinuria Malnutrition Maple Syrup Urine Disease Glutaric Aciduria Type 1 Medical Nutrition Products Methylmalonic Acidemia Propionic Acidemia

Home Page: www.navamedic.com

Henrik Ibsensgate 100
Oslo, 0255
Norway
Phone: 47 67 11 25 40


Officers

Name Title
Ms. Kathrine E. Gamborg Andreassen Chief Exec. Officer
Mr. Lars Hjarrand Chief Financial Officer
Mr. Ole Henrik Eriksen Chief Operating Officer
Ms. Astrid J. Torgersen Bratvedt Chief Scientific Officer
Mattias Von Hartmann Marketing and Sales Director

Exchange: OL

Country: NO

Currency: Norwegian Krone (kr)

Forward PE: 0
Trailing PE: 70
Price-to-Book MRQ: 3.0369
Price-to-Sales TTM: 1.5734
IPO Date:
Fiscal Year End: December
Full Time Employees: 28
Back to stocks